Bringing cell & gene therapy from breakthrough science to reliable clinical manufacturing demands more than innovation—it requires analytical rigor and process discipline. Yet with complex biology, evolving regulatory expectations, and accelerating development timelines, many programs face the same challenge: how to scale confidently without sacrificing consistency, quality or speed.

Join this expert led discussion from Citeline and Thermo Fisher Scientific as they share real-world strategies for building analytical strength early, standardizing critical assays, and leveraging scalable platforms to reduce uncertainty and accelerate translation. Learn how integrated analytical approaches are helping leading CGT programs move faster, make better decisions, and reach patients with greater confidence.